Clinical pathology – Vet Clin Path Journal Thu, 23 Jun 2022 18:57:21 +0000 en-US hourly 1 Clinical pathology – Vet Clin Path Journal 32 32 virtual biomarkers: an emerging high-throughput research tool | Webinars Thu, 23 Jun 2022 18:21:01 +0000

Thu Aug 11 2022 1:00 PM EDT


Pathology underpins every facet of healthcare, influencing more than 70% of all medical decisions. It is used in every phase of preclinical and clinical drug development, in every tumor repository and biobank, and in a growing majority of standard and companion diagnostics for precision cancer care. However, such studies, whether performed traditionally by visual microscopy or by new image analyzes enhanced by artificial intelligence (AI), are limited by the number of markers that can be performed on shrinking samples and aging. These samples should also be retained for downstream multiomics analysis.

Yair Rivenson demonstrates how the age-old practice of histopathology can be changed using a digitized process in a non-destructive manner. The process is enabled by virtual staining technology based on machine learning that enables fully digital and virtual multiplex tissue platforms to dramatically improve the quality and quantity of a pathological sample. This is accomplished by protecting sample integrity, minimizing pre-analytical degradation of target analytes, and revolutionizing the storage and processing of cancer-relevant biospecimens.

Rivenson also discusses additional benefits of the technology. These benefits include laboratory durability and digital outputs that can be seamlessly integrated into downstream AI image analysis software, providing full characterization of cellular processes in minutes.

Who should attend:

Researchers and engineers working in pathology who are interested in recent advances in the field. Professionals working with AI in the fields of biophotonics. Individuals interested in test and measurement, imaging, microscopy and spectroscopy, in areas such as cancer research, histopathology, medicine and pharmacy.

About the presenter:

Yair Rivenson, Ph.D., is CEO and co-founder of Pictor Labs. Prior to taking an active role in Pictor Labs, he was an Assistant Professor and Research Fellow in the Department of Electrical and Computer Engineering at UCLA. There Rivenson developed the core technologies that would become the foundation of Pictor. He transitioned to his professorship after three years of postdoctoral work in Professor Aydogan Ozcan’s lab at UCLA.

Rivenson’s intellectual property portfolio includes one issued and 11 pending patents, over 65 co-authored journal publications and over 110 peer-reviewed conference presentations. His achievements have been recognized by senior members of IEEE and Optica, as well as the UCLA Chancellor’s Award for Postdoctoral Students. Rivenson is editor of the IEEE Photonic Log.

Research & TechnologyMicroscopyartificial intelligenceBiophotonicscancermedicalpharmaceutical

Large UBH Pathology Lab to Change Regional Medical Landscape Tue, 21 Jun 2022 22:17:37 +0000

The Chronicle

Nqobile Tshili, columnist
A MAJOR pathology laboratory is under construction at the United Hospitals of Bulawayo (UBH) in Bulawayo, the impact of which is expected to be felt in the south of the country through improved diagnostic services.

Currently, UBH uses three rooms where diagnostic tests are performed.

Authorities believe the pathology center being built will be one of the largest public hospitals in the country.

The pathology lab project had been stalled for years and when President Mnangagwa visited UBH last year, he ordered the project to be completed.

Once completed, more laboratory scientists will be recruited and a number of hospitals will benefit from the testing services offered at UBH.

When a Chronicle news crew visited the referral hospital on Monday, construction was underway, with officials expecting the structure to be completed by the end of the year.

The UBH experienced a major transformation under the Second Republic in accordance with the government’s desire to guarantee the accessibility of health care to all.

Earlier in the year, the hospital’s pediatric unit was expanded to provide services that were previously only available at Mpilo Central Hospital.

UBH is also home to the Bulawayo Orthopedic Hospital, the first of its kind in Zimbabwe and only the third in Southern Africa, and freely treats children with deformities. It was opened by President Mnangagwa last year.

The government has also renovated the hospital’s Old Bartley’s Memorial Block (BMB) into a 50-bed Covid-19 isolation center with state-of-the-art equipment, which the president also opened last year.

UBH’s acting chief executive, Dr. Narcisius Dzvanga, said they were excited to build such a massive lab.

“What you see over there is a laboratory under construction.

It will be one of the largest laboratories in the country and will improve the delivery of pathology services in the region.

“It is going to house several departments that fall under the department of pathology and offer pathology services,” Dr. Dzvanga said.

He said construction of the lab had been stalled for years until President Mnangagwa stepped in when he came to commission the orthopedic center and the UBH Covid-19 isolation center in May of 2019. last year.

“Construction started a week ago, according to the schedule of works, we believe that the superstructure will be finished by the end of December.

Subsequently, there will be the loading of the rooms, which means equipping the hospital.

And if all goes according to plan, we’ll see it functional by the end of 2023 or mid-year at the earliest.

They work at supersonic speed; we are impressed that they are serious and that we are serious as well,” he said.

“The president came to open BNB and open this children’s hospital, he said Dvanga, I want to find this building higher than you. The President is aware of this, the Vice President is aware of this and the Department of Health and Child Care is aware of this. »

Dr Dzvanga said the government is funding the construction of the pathology lab and a private contractor has been hired to build the structure.

UBH’s acting clinical director, Dr. Harrison Rambanapasi, said the construction of the pathology lab is expected to transform the delivery of health care in the region.

He said that since UBH is a referral hospital for other hospitals in the Matabeleland region, the referred patients will benefit from the tests that will be carried out at the laboratory.

“The challenge we have right now is that the hospital lab we use is very, very small in terms of the physical space available.

This limits the number of medical laboratory scientists we can hire as they will all be crammed into small rooms,” Dr Rambanapasi said.

“It limits the number of machines you can fit there to perform a number of tests required for patients with various conditions.

So building this lab will give us more space and allow us to expand the scope of testing we can do.

He said the lab will also have enough rooms to accommodate health workers who will be on night duty.

“Basically what I can say is that it’s one of the biggest labs in public hospitals,” he said.

The government has already completed construction of the National Pathology Research and Diagnostic Center at Midlands State University.

— [email protected] ]]> Dr. Vizarath Rasool Khan’s free mega medical camp ended successfully Sat, 18 Jun 2022 06:19:00 +0000

Hyderabad: Dr. Vizarath Rasool Khan’s Free Mega Medical Camp at Shadan Hospital successfully ended on June 15, 2022. The camp started on May 23, 2022. Thousands of patients not only from Twin Cities and Telangana districts , but also neighboring states got benefited from this camp.

Publishing the details of the camp, Superintendent of Shadan Hospital, Dr. Vasantha Prasad, the ex-DME, said that 60,000 to 65,000 patients were treated during the 20 days of the camp, of which 15,000 to 20 000 were treated on an outpatient basis.

About 12,000 major and minor surgeries were performed, including caesarean sections, kidney stones, hernias, cataracts, and minor and major bone fractures. Under this camp, approximately 75,000 blood tests were performed, including cytopathology, hematology, microbiology, histopathology, clinical pathology, bio RT PCR and chemistry tests.

The Superintendent further stated that approximately 250 normal deliveries were made. Radiology and imaging tests considered to be the most expensive tests were carried out free of charge. These tests include CT scan 800, ultrasound approximately 3500, ECG and EEG 2500, mammogram approximately 350, barium study 550, CT guided FNAC tests 150, X-ray 5500 and 2D ECHO tests 550.

Dr. Sarab Rasool Khan congratulated the Superintendent of the Hospital, Dr. Vasantha Prasad, Ex-DME, Dr. Sushil Pakhinathan, Dean of Shadan Institute of Medical Sciences, Dr. Prahlad, Medical Director of the Shadan Hospital, Dr. Dinesh Raj Mathur, Director of the Academy and Head of all Super Specialty Departments, Registrars and Medical Officers, PG Doctors as well as Nursing and Paramedics.

Dr Khan also thanked the print, electronic and medical social media for coverage of the camp.

“The free medical camp has ended, but hospital services will remain available for the deserving poor,” Dr Khan said.

Dr Khan informed that Dr Mohammed Vizarath Rasool Khan Free Camp, Aziz Nagar RR District will continue till 22nd 2022 with full medical staff available 24 hours a day for patient service to ensure the comfort of all who come from the city and districts as well as neighboring states.

Transportation and free catering facilities will be provided for visitors to Dr. Mohammed Vizarath Rasool Khan Hospital.

24 hour inquiries are available on the following helplines: 8676311747, 8686285796, 900098544, 9849019535, 9885751975,

“I Am Gen Z”: How the younger generation braves technological submersion Thu, 16 Jun 2022 05:00:18 +0000

Technology has always been a double-edged sword. But Gen Z has been forced to wield both sides of the blade.

In 1997, when the oldest Gen Zers were born, Liz Smith joined a Silicon Valley startup called Yahoo! What started as a bunch of internet misfits has turned into something of a “Frankenstein’s monster,” Smith told AdExchanger.

Generation Z, an age range currently between about 9 and 24, should have been afraid of the monsters they carried around with them, not the imaginary monsters under their bed.

Smith, who left Yahoo! for film school, was inspired by the effects of technology on children after reading Dr. Jean Twenge’s book on the subject, iGen. This inspiration turned into the film I Am Gen Z, which began screening this year.

“The term ‘digital native’ is used to describe both Gen Z and Millennials, but these two generations are incredibly different – technology is a key differentiator in terms of Gen Z’s growth,” said said Kathy Sheehan, senior vice president of ENGINE-owned Cassandra, a marketing consultancy that advised on the film’s production.


The film sets the scene in 2007, the year Apple unveiled the iPhone, and soon after Facebook opened up to everyone, not just students.

The most popular social media at the time, MySpace, had 120 million users. Facebook, at 80 million, has started thinking about how to catch up.

The solution? Algorithms.

“The business model for all of these social platforms is ad-based,” said tech and science journalist Clive Thompson, who appears throughout the film. “These companies want to keep users on their feeds all day. But how are they going to do it? By training algorithms to look for patterns of engagement.

We’ve agreed to free services in exchange for our data – but that data is used to perpetuate divisive and irritating content because it’s more likely to get clicks, said author and journalist Jamie Bartlett. “It’s content for people’s most basic instincts.”

social game

Neuroscientists and clinical psychologists in the film liken the inner workings of social algorithms to the workings of addiction.

“The technology is really, really good at finding ways to make sure that this feedback is steady but not too predictable,” said neuroscientist Dr. Jack Lewis. “The one thing we know from addiction research is that it’s these ‘near misses’ that are most addictive.”

The appearance of what might have been — that near miss on the slot machine or the girl on Instagram who’s skinnier than you — serves as a call to action that encourages certain, often unhealthy, behaviors.

And algorithms that can mimic addiction patterns have an easier time latching onto underdeveloped brains. “In adolescence, gray matter shrinks ever so slightly as the brain cuts off neural synapses that aren’t needed,” Dr. Lewis said. “At the same time, white matter matures, helping remaining neurons become more efficient at sending and receiving messages.”

In other words, the algorithms are ready to take advantage of children’s neural reward systems.

The mental health crisis

The film connects the rise of algorithmic social media to social and mental health issues among teens and children.

According to the CDC, suicide rates among children ages 13 to 24 soared 56% between 2007 and 2017, said Tim Kendall, former director of monetization at Facebook.

But for young women aged 13 to 18, the rate is doubled.

Perhaps the most alarming effect of social media on young women is the glorification of eating disorders. From “thinspiration” trends to “pro-ana” (pro-anorexia) forums online, eating disorder behaviors go beyond normalization — they are encouraged.

Eating disorders have become a “social phenomenon,” said Dr. Tracey Dennis-Tiwary, a professor of psychology and neuroscience who conducts NIH-funded research on teen suicide risk. “The children come together and agree to share the experience together. But like any form of addiction or self-harm, eating disorders are a very isolating condition. By incubating people encouraging the behavior, social media has become an “amplifier” for eating disorders, she said.

Whose problem?

But therein lies the rub – like much of the internet, social media is built on competition for ad revenue, so patterned identification and amplification is the nature of the beast.

“If you ruled out Apple or Google to rebuild the phone from scratch, I think they’d get rid of a lot of those hooks built into the phones — even some of the notification glitches,” according to Kendall, formerly of Facebook.

Signs of improvement

Gen Zers are more than “screen-addicted, emotionally paralyzed waifs,” said Dr. Dennis-Tiwary. Teens and 20-somethings are acutely aware of their own social paradoxes, perhaps more so than anyone.

When director Liz Smith began collecting feedback on the film, she found that only older generations were surprised by the presentation. “The older generations are gone [from the movie] feeling quite shocked and depressed, as Gen Z says, “Yeah.” This is our reality,” Smith said. “They are much less shocked by the film.”

From self-improvement practices and open discussions about mental health to social and political organizing, Gen Zers are “incredibly engaged in the world around them,” said Dr. Dennis-Tiwary. “They have to be – we handed them this utter mess of a world.”

RI-Based MindImmune Therapeutics Raises $12.4M in Series A Funding Tue, 14 Jun 2022 14:56:57 +0000

Tuesday, June 14, 2022

View larger +

Image file

MindImmune Therapeutics Inc., a Rhode Island-based drug discovery company, says it is “pioneering a new approach to treating Alzheimer’s disease and other neurodegenerative diseases.” It announced that it had closed a Series A financing of $12.4 million.

Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (a subsidiary of the Slater Technology Fund) and several private investors. Use of proceeds from the financing will help MindImmune advance its flagship preclinical development program, targeting Alzheimer’s disease as a primary indication.

In the United States, an estimated 5.8 million Americans have been diagnosed with Alzheimer’s disease. Statisticians predict that over the next 30 years, 13.8 million people could live with Alzheimer’s disease if researchers fail to prevent or find a cure for the disease.


MindImmune was founded by co-founders Stevin Zorn, Ph.D, Frank Menniti, Ph.D., and Robert Nelson, Ph.D., who originally met as scientific collaborators in research on the central nervous system (CNS) at Pfizer. After Pfizer, Drs. Zorn and Nelson joined H. Lundbeck AS, a leading CNS-focused pharmaceutical company, where they created one of the first pharmaceutical research groups targeting neuroinflammation. Following his tenure at Pfizer, Dr. Menniti was a co-founder of Mnemosyne Pharmaceuticals (later renamed Cadent Therapeutics), which was acquired by Novartis to further develop its novel NMDA receptor modulators.

MindImmune claims in its announcement that it has “made a fundamental discovery that may be linked to the progression of Alzheimer’s disease”.

According to the company, it has discovered that cells of the peripheral immune system enter and cause damage to neurons with Alzheimer’s disease. MindImmune aims to develop a new therapeutic antibody to act in the peripheral system to prevent immune cells from causing neural damage, thereby reducing cognitive symptoms and slowing the progression of this devastating disease. The company is continuing its research on the premise that this neuro-inflammatory process may be the cause of central nervous system (CNS) damage in a wider range of neurodegenerative diseases.

“We are honored to have the support of existing and new investors, many of whom are recognized for their deep industry expertise in the field of neurodegenerative diseases,” said Stevin Zorn, President and CEO of MindImmune. “With the resources provided, we are excited to accelerate our preclinical R&D activities, aimed at advancing our lead program to the IND candidate stage.”

According to Tracy Saxton, Ph.D., Managing Director of Dolby Family Ventures, “MindImmune has distinguished itself by pioneering a potentially fundamental new approach to modulating the innate immune response in Alzheimer’s disease. We are pleased to support this outstanding group of founding scientists to advance our understanding of the role of the innate immune system in the progression of Alzheimer’s disease, and to nominate a clinical candidate aimed directly at blocking the damage caused by these peripheral immune cells. .

As part of this funding, the ADDF is supporting research into a new way to measure immune cell recruitment in patients with Alzheimer’s disease. This assay is designed to quantify the amount of peripheral immune cells recruited to the CNS in Alzheimer’s disease and potentially serve as a diagnostic and/or biomarker of neuroinflammation in Alzheimer’s disease patients, helping the R&D community in a broad sense as well as the internal program of MindImmune.

Based at the University of Rhode Island, MindImmune enjoys an affiliation with the George & Anne Ryan Institute for Neuroscience, Kingston, RI.

Like this article ? Share it with others.

Health: Medicare startups receive a booster dose Sun, 12 Jun 2022 22:00:00 +0000

We live in an age where digital healthcare disruption is not a choice, but a necessity. GE Healthcare, a leading medical technology company, has formed strategic alliances with growth-stage MedTech startups through its India Edison Accelerator program (launched in 2019) to co-develop innovative solutions that can meet the challenges of the Indian health sector. The Edison platform uses analytics, machine learning (MI), deep learning, and AI to identify actionable insights, prioritize workflows, and deliver personalized patient care. Startups in the current cohort (cohort 3) focus on areas such as cardiology, oncology, and genomics.

Aira Matrix is ​​one of the startups in this group, providing AI-based solutions for life science applications. Its solutions improve the efficiency, diagnostic accuracy and turnaround times of pathology, microbiology and ophthalmology workflows for pharmaceutical and healthcare laboratories. “We have seen immense benefits from the Edison Accelerator program,” said Chaith Kondragunta, CEO of Aira Matrix. “During the selection process, we realized that the focus of our collaboration will be diagnostic, prognostic and predictive solutions for prostate cancer. We were delighted to share a common goal with GE Healthcare of delivering cost-effective diagnostics, improving patient experience, increasing healthcare workflows and achieving high-throughput processes across the continuum. of care. The startup’s customers and partners include leading hospitals, pharmaceutical companies, CROs and research labs around the world.

Qritive is another start-up to have benefited from the program. With a mission to make cancer diagnosis fast, accurate and affordable, it offers AI-powered solutions that help pathologists in cancer diagnosis. “Solving this healthcare problem can be difficult due to the fragmented nature of the market. GE Healthcare’s India Edison Accelerator program has proven to be the most impactful initiative Qritive has participated in so far,” says its CTO and co-founder, Kaveh Taghipour.

“Startups featured in the third cohort are developing solutions that enable and promote a technology-enabled healthcare ecosystem,” said Girish Raghavan, vice president, Software Engineering, GE Healthcare. For example, a Cohort 3 startup is working on personalizing oncology patient care through genome panel analysis that allows clinicians to match a patient to a therapy that has a higher likelihood of working for him. Cohort 3 startups are also developing solutions aimed at reducing the cognitive load of physicians.

“At GE Healthcare, we want to nurture the startup ecosystem and help create healthcare solutions by leveraging the Edison platform and decades of GE Healthcare expertise,” says Raghavan. Edison enables the deployment of Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant healthcare solutions that can aggregate, correlate, analyze, process, display and share data from connected medical devices, sensors and health information systems. From a business perspective, it will reduce infrastructure and development expenses for startups, as it provides predefined services and opens up global collaboration opportunities.

“Startups can herald the dawn of digital healthcare in India, providing affordable solutions with reach beyond Tier I and II cities,” says Raghavan. The Edison platform currently powers more than 50 applications that span clinical service lines. These solutions are deployed through the cloud, data centers, or on-premises across the healthcare spectrum. “We are also developing a digital health platform to help providers accelerate their digital transformation. This platform aims to enable hospitals and healthcare systems to efficiently deploy clinical, analytics and AI tools that would support improved care delivery,” he said.

Parents honor their son’s name with veterinary scholarship for Blinn College Fri, 10 Jun 2022 23:00:53 +0000

BRYAN, Texas — A Blinn College Vet Tech alumnus is helping future generations in veterinary medicine.

A tragic accident took the life of Chase Stone in September 2021. Today, his parents are honoring his memory by creating a scholarship for future Blinn Vet Tech students.

Instructor and clinical coordinator for the Blinn Vet Tech program, Jessica Salazar Garza says she has worked closely with Chase.

“I taught Chase when he was a freshman. I had him in a few classes, including radiology and clinical pathology,” Garza said.

Blinn offers a two- and three-year blended veterinary medical education. Their cohorts are no larger than 11 students at a time, allowing them to develop a close relationship.

“They were always together studying, and it was great to see him interacting with everyone, and everyone having a great time. It’s such a joy to be with him, but overall, it’s he’s a great student,” Garza said.

Stone’s parents would like to share Chase’s passion for veterinary medicine with other aspiring students as they honor their son’s memory.

“I know they did this in memory of Chase alive. Animals and animal care were Chase’s passion and it really shined through when he started working closely with these animals and his parents knew, his classmates knew, and we knew. It was his passion, so seeing as they were able to create this scholarship in his name…it ensures that his memory lives on,” Garza said.

Garza says Chase was a shining light in the program. She can’t wait to see the lucky potential student who shares the same passion he has for animals.

New and returning students focusing on the Vet Tech program are eligible for the scholarship.

Lucem Health™ Announces Innovation Collaboration to Bring AI/ML to the Frontlines of Healthcare Thu, 09 Jun 2022 14:30:00 +0000

RALEIGH, North Carolina, June 9, 2022 /PRNewswire/ — Lucem Health™ today launched the Lucem Health Innovation Collaborative, a partnership program designed to bring clinical AI/ML innovation to the front lines of healthcare. The collaboration will help digital health innovators create, deploy and commercialize transformational solutions powered by artificial intelligence and machine learning models.

Clinic-focused AI is advancing rapidly, but bridging the gap between the potential benefits of models and their real impact is daunting. AI models are driven by data, and health data is often siled and difficult to access. AI models should be integrated into existing clinical applications and workflows; Yet vendors often view models as opaque black boxes that are hard to explain, which can lead to limited adoption and access.

Alain Aberdeenfounder of Ground Truth Labs, said, “We are thrilled to partner with Lucem Health to release our AI models from the Digital Pathology Lab at Oxford University and on the front lines of health care.”

Lucem Health created the Innovation Collaborative to forge collaboration between AI developers and digital health innovators. They will develop new solutions to help clinicians make better decisions, diagnose earlier, improve efficiency and better serve patients. The collaboration is powered by Lucem Health’s comprehensive and agnostic platform to innovate, deploy, adopt and continuously improve clinical AI.

Jack coatsCEO of CardioWise, Inc., said, “We are very pleased to partner with Lucem Health to bring SQuEEZ, our cardiac AI solution, to Lucem Health’s Multimodal Model Deployment Platform.

“AI has the potential to revolutionize the way healthcare is delivered,” said Sean Cassidy, CEO, Lucem Health. “The challenge of realizing the potential of AI is not about doing data science and developing algorithms; it’s about understanding that clinical AI, to be relevant, must be integrated into the ecosystem. of healthcare data and applications Our Innovation Collaborative partners have a “solution first” mindset that considers all the requirements that must be in place for AI to be useful, reliable and adopted.”

“Lucem Health is ushering in a new wave of AI in medicine, and this collaboration is an important step in bringing AI/ML innovation to the front lines of healthcare,” said AvoMD CEO, Yair SapersteinMDMPH.

The founding members of the Innovation Collaborative include AI/ML developers:

  • AIQSolutions
  • AlgoDx
  • Cardiologists
  • CardioWise
  • celsium
  • First biomedical ascent
  • Ground truth labs
  • MedKal Health
  • Mpirik
  • Rinicare

And digital health innovators:

  • AvoMD
  • Brunswick MedTech
  • eCordum
  • NxgenPortName
  • Stel Life
  • Turtle Health

About Lucem Health:

Lucem Health™, launched with Mayo Clinic in conjunction with investor partners Commure (a General Catalyst company) and Rally Ventures, enables healthcare visionaries to quickly bring AI-powered insights to the point of care. Digital health innovators develop transformative clinical solutions and take them from the bench-to-bedside to the front lines of healthcare on a single integration platform. Visionary clinical leaders deploy new data and information seamlessly into clinical workflows while ensuring clinicians trust, embrace and see value in them. For more information, visit

Media Contact:
For Lucem Health
Mary Blair
[email protected]

SOURCE Lucem Health

Pathology and prevalence of dry eye Tue, 07 Jun 2022 21:15:51 +0000

Laura M Periman, MD: Hello, I’m Laura Periman from Seattle, Washington. I am a board-certified ophthalmologist and cornea-trained ocular surface disease expert. I also do clinical research at the Periman Eye Institute. It’s great to be here.

What is dry eye? All day every day, we treat it and do clinical studies looking for innovations to treat it more effectively. In a nutshell, what you need to understand about dry eye is that it’s a busy, noisy, messy umbrella term for probably about 30 different clinical sub-diagnoses. There are all those conspirators that come with dry eye. But the consequence is interruptions in vision, tear film stability, eye discomfort and, above all, inflammation.

There is a well-described and well-understood impact on what we call neurosensory compromise in dry eye disease. This means that the electrical wiring, so to speak, which constantly monitors the quality of your tears and provides feedback, is damaged in some way. This is where modalities such as neural stimulation come in, which is particularly beneficial in cases of long-standing dry eye and conditions associated with peripheral neuropathy, such as diabetes, post refractive surgery and post surgery. -cataract. All of these conditions can negatively impact the electrical wiring of a healthy and stable tear film. You lose the ability to maintain what we call a homeostatic stable tear film, or even state. That’s when you have those impacts on inflammation, quality of vision, ocular surface damage, and neurosensory compromise. It’s a never-ending answer, but if you think of a circus tent with about 30 different animals running around inside while all the lights are off, that’s dry eye.

Our understanding of what a typical dry eye patient looks like has changed a lot over time. We see children and younger adults presenting with dry eye. There is no characteristic typical patient with dry eye. It handles all races, hormonal statuses and ages. It’s ubiquitous, and there are several risk factors that go with it. Lifestyle, screen time, contact lens wear, nutrition, underlying medical conditions, diabetes, high blood pressure, and any medications needed to control these underlying medical conditions contribute all to dry eye. There are all these funnels that contribute to the dry eye trough, which helps explain why it’s difficult to get the right diagnosis and treatment with the tools we have.

The prevalence of dry eye disease in the United States is estimated at between 16 and 50 million people. The reason for this variability lies in how and when these epidemiological studies define dry eye. We now have advanced diagnostics and approaches to diagnosing dry eye disease that have expanded what all of this means. That’s why you’re going to see such variability in the numbers.

Take a conservative number. While 17 million people suffer from dry eye, just over a million receive prescription medication. This is a problem because we know that the natural course of disease is progression if left untreated. And once you progress, the number of procedures and prescriptions and things you need to do to stabilize that tear film and make that patient functional and more comfortable increases dramatically if not detected and treated early. The prevalence varies relatively little. Then, as more diagnostic tools become available, we will have the power to determine exactly which variety of dry eye is occurring. We will be able to identify clinical risk factors and then be much more targeted and specific to patient needs from a prescribing and intervention perspective.

Transcripts edited for clarity.

US deployed 1,200 monkeypox vaccines in response to outbreak Mon, 06 Jun 2022 02:04:00 +0000

By Jacqueline Howard, CNN

(CNN) – As the number of monkeypox cases rises amid an ongoing global outbreak, U.S. health officials said Friday they were stepping up testing and contact tracing and expanding access to vaccines. and treatments.

As part of those efforts, about 1,200 doses of the monkeypox vaccine have been offered in the United States, said Dr. Raj Panjabi, White House senior director for global health security and biodefense.

“We want to ensure that those exposed to high risk have timely access to vaccines and, if they become ill, can receive appropriate treatment. To date, we have delivered approximately 1,200 vaccines,” Panjabi said. “And 100 treatment courses in eight jurisdictions, and we have more to offer the states.”

Massachusetts healthcare workers treating patients with monkeypox were among the first to receive vaccines to protect them against the virus.

In the United States, the two-dose Jynneos vaccine is licensed to prevent smallpox and specifically to prevent monkeypox. Another smallpox vaccine licensed in the United States, ACAM2000, can also be used for monkeypox.

To date, more than 120 orthopox PCR tests have been performed in the United States as part of outbreak surveillance.

“That’s only a fraction of what’s available,” Panjabi said, adding that 67 labs across 46 states — part of a network known as the Laboratory Response Network — have the “collective capability.” to perform more than 1,000 tests per day.

“So what we’re working on now is making sure that testing capacity is used,” he said. People with symptoms of monkeypox are encouraged to see a health care provider, and providers are asked to test if they suspect someone might have monkeypox.

There could be ‘community-level’ spread, CDC official warns

On Friday, officials from the US Centers for Disease Control and Prevention urged clinicians to be on the lookout for possible cases of monkeypox, as the virus could spread at the community level.

Twenty cases of monkeypox have been identified in 11 states, along with an additional case in the United States who was infected and tested elsewhere, said Dr. Jennifer McQuiston, deputy director of the CDC’s Division of Pathogens and High-Consequence Pathologies. .

All patients are recovering or have recovered, and those who still have a rash are advised to stay home and isolate themselves from others until fully recovered.

“I want to emphasize that this could happen in other parts of the United States. There could be community-level transmission, and that’s why we really want to increase our surveillance efforts,” McQuiston said. “We really want to encourage doctors that if they see a rash and they’re worried it’s monkeypox, to go ahead and test that.”

She added that the rashes appearing as a result of monkeypox infections in this outbreak can be subtle and easily confused with other types of infections, especially sexually transmitted infections – and there could be co-infections. of monkeypox with STIs.

McQuiston said the rash from a monkeypox infection usually appears as “deeply seated” and “well-rounded” lesions that progress to raised or fluid-filled pustules. It could be confused with other infectious diseases like herpes or syphilis, she added.

“That being said, we don’t want to downplay this condition. The rash caused by monkeypox virus can spread widely through the body or show up in sensitive areas like the genitals,” McQuiston said. “It can be very painful, and some patients have reported needing prescription painkillers to manage this pain. Wounds can also cause long-term scarring of the skin.”

An analysis of genetic sequence data from cases in the United States indicates that two genetically distinct variants of monkeypox may be circulating, McQuiston said.

Genetic sequence data is “certainly interesting from a scientific point of view”, but “to determine how long the monkeypox virus has been circulating for, it will be necessary to analyze many more sequences from many more patients to start to piece this puzzle together in a clearer way,” she said. “It’s certainly possible that there have been cases of monkeypox in the United States that have gone unnoticed before, but not to a degree raised.”

She added that the risk to the public is still low and that finding cases with distinct lineages is a “positive sign” that the country’s surveillance network is working.

CDC researchers and health officials released a report on Friday describing multiple cases of monkeypox in the United States, noting that “ongoing investigation suggests person-to-person community transmission, and the CDC urges healthcare, clinicians and the public to remain vigilant, institute appropriate infection prevention and control measures, and notify public health authorities of suspected cases to reduce the spread of disease.”

Of the 17 cases described in the report in nine states, all patients had a rash, 14 of them said they had traveled abroad in the 21 days before their symptoms, and all but one identified as male who have sex with men (MSM). Three were immunocompromised. All patients were adults.

“The high proportion of initial cases diagnosed in this outbreak among people who identify as gay, bisexual or other MSM, may simply reflect an early introduction of monkeypox into interconnected social networks; this finding may also reflect verification bias in because of strong and established relationships between some MSM and clinical providers with strong STI services and broad knowledge of infectious diseases, including rare conditions,” the CDC researchers wrote in the report.

“However, infections are often not limited to certain geographic areas or population groups; because close physical contact with infected people can spread monkeypox, anyone, regardless of gender or sexual orientation, can contract and spread monkeypox.”

Globally, according to World Health Organization officials, more and more countries are reporting cases of monkeypox that have never seen the virus before.

“Cases have been reported in 26 countries” where the virus is not endemic, said Maria Van Kerkhove, head of emerging diseases and zoonoses and WHO technical lead on Covid-19, during a point press Thursday. She added that more than 600 cases have been identified in these countries.

“As surveillance increases, as attention increases, we expect more cases to be identified,” she said. “Many public health outbreak investigations are ongoing.”

Rosamund Lewis, the WHO’s technical lead for monkeypox, said on Tuesday that this outbreak was different from previous ones because “we are all seeing cases appear in a relatively short period of time.”

“What we’re seeing now started as a small cluster of cases, then investigation quickly led to the discovery of infections in a cluster of men who have sex with men, and that led to other investigations, and so we don’t yet know what the source of the actual outbreak is,” Lewis said. “What’s most important now is not to stigmatize.”

™ & © 2022 Cable News Network, Inc., a WarnerMedia company. All rights reserved.